{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:51:42Z","timestamp":1787014302026,"version":"build-2736575974"},"reference-count":50,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T00:00:00Z","timestamp":1625875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Helicobacter"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Vonoprazan fumarate is a novel potassium\u2010competitive acid blocker more effective in suppressing acid production than proton pump inhibitors (PPIs) and when combined with antibiotics has been used to eradicate\n                      <jats:italic>Helicobacter pylori<\/jats:italic>\n                      (\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori)<\/jats:italic>\n                      infection. However, it has not yet been examined in an Australian setting. This study aimed to report on the efficacy and safety of vonoprazan\u2010containing antibiotic combination therapies in the eradication of\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A single\u2010center, exploratory, clinical review of patients 18\u00a0years or over, positive for\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori<\/jats:italic>\n                      on Urea Breath Test (UBT), and\/or histopathology who underwent a 10\u2010day treatment of combination antibiotics plus vonoprazan between January 2017 and September 2019 was conducted. Eleven different combinations of antibiotics that included 2\u20135 different antibiotics predominantly amoxicillin, rifabutin, levofloxacin, furazolidone, nitazoxanide, and tetracycline were included. The eradication success was based on negative UBT results and\/or histopathology results after the treatment. Descriptive statistics were summarized.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One hundred and fifty\u2010three patients (Female\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a074, 48%) with a positive for\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori<\/jats:italic>\n                      were treated with vonoprazan\u2010containing antibiotic combination therapy during the study period. Of the 153 patients, 48 (31%) had previously failed a PPI\u2010based\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori<\/jats:italic>\n                      treatment. Follow\u2010up was available for 66\/153 (43%) patients. In those who completed follow\u2010up, overall eradication was achieved in 97% (64\/66) of patients. In the subgroup of patients treated for the first time, eradication was achieved in 100% (44\/44). In those who had failed prior, non\u2010vonoprazan\u2010containing treatment, eradication was achieved in 91% (20\/22) of patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Vonoprazan\u2010containing antibiotic therapy is an effective\n                      <jats:italic>H<\/jats:italic>\n                      .\n                      <jats:italic>\u00a0pylori<\/jats:italic>\n                      eradication treatment. It is capable of achieving 100% efficacy in patients treated for the first time and even 91% efficacy in patients with previous eradication failure. Subsequent studies utilizing a factorial design will be needed to optimize each regimen as most regimens contained more than two antibiotics.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/hel.12830","type":"journal-article","created":{"date-parts":[[2021,7,11]],"date-time":"2021-07-11T00:48:15Z","timestamp":1625964495000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Combinations of antibiotics and vonoprazan for the treatment of\n                    <i>Helicobacter pylori<\/i>\n                    infections\u2014Exploratory study"],"prefix":"10.1111","volume":"26","author":[{"given":"Anoja W","family":"Gunaratne","sequence":"first","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Hamblin","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annabel","family":"Clancy","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleja Jane Marie C","family":"Magat","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Vic M","family":"Dawson","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Tu","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-4698","authenticated-orcid":false,"given":"Thomas J","family":"Borody","sequence":"additional","affiliation":[{"name":"Centre for Digestive Diseases Five Dock NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,10]]},"reference":[{"issue":"8336","key":"e_1_2_10_2_1","first-page":"1273","article-title":"Unidentified curved bacilli on gastric epithelium in active chronic gastritis","volume":"1","author":"Warren JR","year":"1983","journal-title":"Lancet"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00054-05"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14561"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2005.tb06668.x"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.12.036"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i19.5610"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i16.2017"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2009.11.009"},{"issue":"3","key":"e_1_2_10_10_1","first-page":"728","article-title":"Guidelines for prevention of NSAID\u2010related ulcer complications. Practice parameters committee of the American College of gastroenterology","volume":"104","author":"Lanza FL","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91084-0"},{"key":"e_1_2_10_12_1","first-page":"1","article-title":"Schistosomes, liver flukes and Helicobacter pylori","volume":"61","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"1994","journal-title":"IARC Monogr Eval Carcinog Risks Hum"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i20.3248"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12751"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1159\/000505367"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1177\/030006057500300205"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(78)90758-8"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1989.tb101251.x"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-008-0098-4"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.04.011"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.563"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(99)00051-5"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15352"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.01560"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4866-6"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.110.170274"},{"key":"e_1_2_10_27_1","first-page":"11","article-title":"Vonoprazan fumarate, a novel potassium\u2010competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date","author":"Sugano K","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9781212"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.5056\/jnm18029"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1159\/000504939"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311304"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12495"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.2521-18"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3734"},{"key":"e_1_2_10_35_1","first-page":"608","article-title":"Helicobacter pylori: the latest in diagnosis and treatment","volume":"37","author":"Stenstroem B","year":"2008","journal-title":"Aust Fam Physician"},{"key":"e_1_2_10_36_1","unstructured":"https:\/\/www.australianclinicaltrials.gov.au\/researchers\/good\u2010clinical\u2010practice\u2010gcp\u2010australia"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2008.01.011"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph13100276"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14130"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-5378.2003.00158.x"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hel.12719"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-319954"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2003.022111"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13461"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/4385161"},{"key":"e_1_2_10_46_1","first-page":"409","article-title":"Worldwide H. pylori antibiotic resistance: a systematic review","volume":"19","author":"De Francesco V","year":"2010","journal-title":"J Gastrointestin Liver Dis"},{"issue":"5","key":"e_1_2_10_47_1","first-page":"301","article-title":"Helicobacter pylori eradication \u2013 an update on the latest therapies","volume":"43","author":"Yaxley J","year":"2014","journal-title":"Aust Fam Physician"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2006.02793.x"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1159\/000502287"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics9100671"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.57"}],"container-title":["Helicobacter"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hel.12830","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hel.12830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:20:08Z","timestamp":1693300808000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hel.12830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,10]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/hel.12830"],"URL":"https:\/\/doi.org\/10.1111\/hel.12830","archive":["Portico"],"relation":{},"ISSN":["1083-4389","1523-5378"],"issn-type":[{"value":"1083-4389","type":"print"},{"value":"1523-5378","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,10]]},"assertion":[{"value":"2021-05-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e12830"}}